The fatty acid biosynthetic factory is an important target in the fight against this infectious bacterium. The fatty acid synthase (FAS) is considered one of the most complex cellular machines.

Sagimet Biosciences Announces Completion of Patient Enrollment in Phase 2b ‘FASCINATE-2’ Clinical Trial with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Non ...

Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion. npj Breast Cancer, 2024; 10 (1) DOI: 10.1038/s41523-024-00656-0 ...

Further experiments showed that NPD6433 and cerulenin, another fatty acid synthase inhibitor, were able to kill numerous yeast species in culture.

Fatty acid synthase (FAS) is highly expressed in many human cancers, including lung cancers. Previous work has shown that blocking FAS activity by cerulenin, a natural antibiotic, or C75, a ...

The company is also investigating BJT-188, a preclinical liver-targeted fatty acid synthase (FASN) inhibitor, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

TVB-2640, a fatty acid synthase inhibitor, significantly reduced liver fat and serum biomarkers of liver injury, fibrosis and inflammation in patients with nonalcoholic steatohepatitis according ...